Oncotarget

Meta-Analysis:

Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis

Xiaowei Mao, Yujun Zhang, Fangfang Xie, Xiaoxuan Zheng and Jiayuan Sun _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:78057-78067. https://doi.org/10.18632/oncotarget.20291

Metrics: PDF 1324 views  |   HTML 1838 views  |   ?  


Abstract

Xiaowei Mao1, Yujun Zhang1, Fangfang Xie1, Xiaoxuan Zheng1 and Jiayuan Sun1

1Department of Endoscopy and Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, PR China

Correspondence to:

Jiayuan Sun, email: [email protected]

Keywords: EGFR, peripheral blood, advanced NSCLC, mutation, meta-analysis

Received: December 28, 2016     Accepted: June 01, 2017     Published: August 16, 2017

ABSTRACT

Background: Apply peripheral blood as a surrogate for detecting epidermal growth factor receptor mutation status in tumor, also called liquid biopsy, has been reported to be a feasible method in patients with advanced non-small lung cancer. But the diagnostic yield varies in different studies.

Methods: A meta-analysis was carried out to evaluate the sensitivity and specificity of peripheral blood in detection epidermal growth factor receptor mutation status in advanced non-small lung cancer patients. Publications up to October 2016 were searched using PubMed, Embase and Web of Science databases. Sensitivity, specificity and other parameters were pooled using the bivariate mixed-effects regression model.

Results: Fifteen studies meeting the inclusion criteria were included. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds ratio were 0.69 (95% CI: 0.59~0.78), 0.97 (95% CI: 0.94~0.99), 23.1 (95% CI: 11.6~46.1), 0.32 (95% CI: 0.23~0.44), 73 (95% CI: 33~159), respectively. The summary receiver operating characteristic curve was 0.93 (95% CI: 0.91–0.95).

Discussion: Detecting epidermal growth factor receptor mutation in peripheral blood is a reliable and non-invasive method in patients with advanced non-small lung cancer. More sensitive detection methods are required to increase the sensitivity of liquid biopsy of ctDNA.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20291